The COVID-19 pandemic threatens to reverse recent progress in reducing the global burden of tuberculosis. The global number of deaths for tuberculosis could increase by around 200.000–400.000 in 2020 alone, as result of essential tuberculosis services disruptions due to the reallocation of human, financial and other resources from tuberculosis to the COVID-19 response, as reported by WHO: https://bit.ly/35KyzD
Ebola vaccine candidates are currently being evaluated in phase I–III clinical trials conducted in Africa, the EU and the US. Although preclinical development of candidate vaccines utilise different platforms, including
The European & Developing Countries Clinical Trials Partnership (EDCTP) is a public-public partnership between countries in Europe and sub-Saharan Africa, supported by the European Union, which since 2003 has been
As part of the strengthening of health systems and in particular the regulation of drugs and health products within the Africlinique project, the headquarters of the World Health Organization (WHO),